This article is authored by Aditya Sharma, head, Process Solutions, India Region, Merck Life Science, New Delhi.

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.

Kennedy has focused his healthcare crusade on his contention that American healthcare prioritizes treating chronic illnesses ...

The FDA and other HHS agencies of interest to the pharma sphere have seen President Donald Trump’s first 100 days as he ...

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

Among other things, Makary breaks some news here by stating, for the first time, that there will be no significant ...

While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by ...

Pertussis, commonly known as whooping cough, is mostly seen in infants and young children. The number of reported cases this year has reached 8485, which is twice as many cases as recorded this time ...

There is common ground. Most adults favor: Preventing chronic diseases (Republicans 86%, Democrats 91%) Protecting against ...